TABLE 2.
Logistic regression analysis on the association between population characteristics and adherence to the tuberculosis drugs in 2017–2018.
| Covariates | cOR (95% CI) | aOR a (95% CI) |
|---|---|---|
| Age, years | ||
| 0–19 | 0.41 (0.13–1.28) | 0.50 (0.15–1.71) |
| 20–34 | 1.15 (0.69–1.91) | 1.04 (0.61–1.77) |
| 35–49 | 1.00 (Reference) | 1.00 (Reference) |
| 50–64 | 0.77 (0.51–1.15) | 0.83 (0.54–1.29) |
| ≥65 | 0.40 (0.27–0.57) | 0.53 (0.35–0.81) |
| Sex | ||
| Male | 1.00 (Reference) | 1.00 (Reference) |
| Female | 1.00 (0.77–1.30) | 1.06 (0.79–1.41) |
| Insurance type | ||
| Health insurance | 1.00 (Reference) | 1.00 (Reference) |
| Medical aid | 0.73 (0.48–1.11) | 0.78 (0.50–1.24) |
| Medical institution type | ||
| Tertiary hospital | 1.00 (Reference) | 1.00 (Reference) |
| General hospital | 0.95 (0.72–1.25) | 0.97 (0.72–1.30) |
| Primary hospital | 0.70 (0.44–1.11) | 0.74 (0.45–1.22) |
| Clinic | 1.54 (0.70–3.36) | 1.23 (0.52–2.88) |
| Regimen type | ||
| Triple regimen (Three among the first-line drugs) b | 1.00 (Reference) | 1.00 (Reference) |
| Quadruple regimen (HREZ, HEZ+Rfb, HREZ+Rfb) | 3.90 (2.76–5.50) | 4.14 (2.78–6.17) |
| Formulation of tablet | ||
| Single tablet | 1.00 (Reference) | 1.00 (Reference) |
| Combination tablet | 1.38 (1.00–1.91) | 1.04 (0.71–1.53) |
| Comorbidities c | ||
| Diabetes mellitus | 0.54 (0.42–0.71) | 0.70 (0.52–0.96) |
| Chronic obstructive pulmonary disease | 0.98 (0.75–1.29) | 1.21 (0.89–1.64) |
| Chronic liver disease | 0.88 (0.61–1.26) | 1.06 (0.71–1.58) |
| Malnutrition | 0.86 (0.63–1.17) | 0.95 (0.67–1.34) |
| Depression | 0.62 (0.43–0.89) | 0.89 (0.58–1.35) |
| Dementia | 0.30 (0.20–0.45) | 0.53 (0.34–0.85) |
| Comedication d | ||
| Systemic steroid | 0.53 (0.35–0.80) | 0.64 (0.41–1.02) |
| Pyridoxine | 0.93 (0.69–1.27) | 0.98 (0.68–1.41) |
| Concomitant drugs d | ||
| 1–4 | 1.00 (Reference) | 1.00 (Reference) |
| 5–8 | 1.47 (1.04–2.07) | 1.27 (0.81–1.98) |
| >8 | 0.86 (0.63–1.18) | 0.92 (0.59–1.41) |
H, isoniazid; R, rifampicin (rifampin); E, ethambutol; Z, pyrazinamide; Rfb, rifabutin; cOR, crude odds ratio; aOR, adjusted odds ratio; CI, confidence interval.
a
Multivariable logistic regression was fully adjusted with all potential confounders.
b
First-line drugs for drug-susceptible tuberculosis: isoniazid, rifampicin (rifampin), ethambutol, pyrazinamide, rifabutin.
c
Comorbidities were assessed during index year.
d
Comedications and concomitant drugs were assessed during 180-days adherence assessment period.